No Significant Correlation Found Between Labor-Inducing Drug During Childbirth and Future Risk of ADHD and Autism Spectrum Disorder in Children, Study Finds
Environmental influences on Child Health Outcomes NIH
Dr. Ndidiamaka Amutah-Onukagha explores the historical and contemporary reproductive struggles faced by women of color in the United States, highlighting challenges such as medical bias, unequal access to resources, and inadequate prenatal care, while also discussing environmental influences on maternal and child health and community engagement strategies.
Children who live in areas with natural spaces (e.g., forests, parks, backyards) from birth may experience fewer emotional issues between the ages of 2 and 5, according to a study funded by the NIH Environmental Influences on Child Health Outcomes (ECHO) program.
A recent study suggests that living in low-income neighborhoods with limited food access during pregnancy may be associated with an increased risk of babies being born small for gestational age or with lower birthweights. Further research is needed to fully understand the relationship and to evaluate potential interventions improving food access during pregnancy and their impact on birth outcomes and child health.
Children who lived in areas with higher levels of airborne lead in their first five years of life appeared to have slightly lower IQs and less self-control, with boys showing more sensitivity to lead exposure, according to a new study from the NIH Environmental influences on Child Health Outcomes (ECHO) Program.
The Utility of Dried Capillary Blood Spots for Exposome Research
An NIH Environmental influences on Child Health Outcomes (ECHO) Cohort study finds that certain organophosphate esters (OPEs) were linked to increased odds of preterm birth, especially in girls.
A new NIH ECHO Cohort study found that early breastfeeding, regardless of the mother’s weight, is linked to a lower risk of obesity in children between ages 2 and 6. The benefits appear stronger for children of mothers who had obesity before pregnancy.
A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no symptomatic or clinical benefit to taking the antidepressant fluvoxamine at a dosage of 100 mg twice daily for 13 days for the treatment of mild-to-moderate COVID-19 symptoms.